After successful launch, confirms additional
$4.2 Million Purchase Order
VANCOUVER, BC, Dec. 2, 2021 /PRNewswire/ - Atmofizer
Technologies Inc. (the "Company" or "Atmofizer")
(CSE: ATMO) (Frankfurt: J3K) is pleased to announce that the
Company has entered into a non-exclusive distribution agreement
with USA Rapid Test, LLC
("USA Rapid Test") under
which USA Rapid Test has placed an
initial purchase order for US$4.2
million personal space, Atmofizer A500s.
USA Rapid Test, based out of
Clearwater, Florida, is an
industry-leading distributor of COVID-19 rapid tests and
distributes to major companies in the healthcare, retail,
hospitality, education and entertainment industries. In accordance
with terms of the distribution agreement, USA Rapid Test will hold non-exclusive rights
to distribute Atmofizer products throughout the United States through online, B2C and B2B
channels.
"There is no comparison to the level of clean air the Atmofizer
produces and selling it as simple as walking into a room that has
one," said USA Rapid Test COO,
Monica Agami. "The technology is
revolutionary and the difference in the air's breathability is
remarkable. We can now create safer 'bubbles' in not just
doctor's offices or hotel rooms but also homes, businesses,
classrooms, or locker rooms."
"We're excited to have USA
Rapid Test as a partner. The scale of their first order is a
testament to their commitment, the momentum in the space and the
size of the market. The air we breathe is at the center of the
conversation today with COVID and it's long overdue." said
Atmofizer CEO, Olivier Centner.
"While today's announcement will help us reach homes, classrooms
and offices throughout the United
States, our mission is much bigger and global. Demand to
integrate and license our sound wave agglomeration technology has
been strong and we welcome the opportunity to work with partners in
the air purification industry to improve their efficacy and
efficiency."
"We proactively approached Atmofizer to be their distributor for
only one reason... it worked for me. I put an Atmofizer A500
in my bedroom and I was no longer a chronic 'wake-up stuffy
everyday' guy" said USA Rapid Test
CEO, David Lee Jensen. "Striving to
help get America back to work and play, safely is at our business
foundation."
About Atmofizer Technologies Inc.
Atmofizer's consumer and industrial solutions are based on its
patent-protected and patent-pending technology for ultrafine
particle agglomeration and neutralization. This capability creates
a revolutionary and more efficient method for addressing the wide
range of dangerous nano-scale particles, viruses and bacteria that
are too small to be effectively managed by conventional HEPA
filters and ultraviolet lights. Atmofizer plans to disrupt the air
treatment industry by improving air safety and purification
efficiency while lowering customers' operational costs.
Atmofizing air refers to the process of using ultrasonic
acoustic waves to agglomerate (cluster together) small particles
into a larger target that is then radiated by ultraviolet light to
neutralize their harmful properties, making the air you breath less
hazardous to your health. Using units that atmofize air in
tandem with HEPA filters can make the HEPA filters work more
efficiently, enable the use of a less-powerful filter and result in
a cleaner and longer-lasting filter that reduces operating costs
and is less of a health hazard to clean or replace.
Atmofizer is patent-pending and patent-protected sole source of
technology to atmofize air and is applying its proprietary
technology in consumer and industrial air purification products
currently manufactured under the Atmofizer brand, as well as in
retail and commercial devices produced by other companies that
integrate Atmofizer technology into their own products under
license. Atmofizer's owned and licensed product lines include
wearable, portable and mobile use for personal air treatment, as
well as larger systems to handle higher air volumes for commercial,
industrial, institutional and residential applications.
About USA Rapid Test
USA Rapid Test began in
June 2020 with a purpose to fill the
dire need for COVID tests that were fast, highly accurate and most
importantly manufactured in the United
States. USA Rapid Test
partnered with a CLIA High-Complexity Lab out of Dayton, Ohio and DG Medical Manufacturing as
the Master Distributor for an industry-first Oral Rinse PCR test.
USA Rapid Test added distribution
for New Jersey based Access Bio,
an FDA EUA Manufacturer of CareStart Antigen and Antibody rapid
tests. USA Rapid Test has built
the marketing, sales process, sub-distributors, fulfillment, and
delivery lines for its products. USA Rapid Test has provided over 500,000
individual COVID0-19 tests and pandemic solution-oriented products
to help several hundred clients in almost all 50 states.
There are a wide variety of industries represented including,
- Hospitality: Hyatt Global, Hilton Group, Westgate
Properties, Vikand Medical Services (Cruise line Industry)
- Pro Sports: ESPN, IMSA/NASCAR (Motorsports), LA Lakers
(NBA), Denver Broncos (NFL), Chicago White Sox (MLB)
- Entertainment: Alvin Ailey Dance Co., New York City
Ballet, IATSE (Theatre Union), The Phantom of the Opera, Eric the
Trainer, multiple Film Production companies
- Education: University of AZ, Parsons College,
State of Rhode Island, private
high-schools
- Retail & Online: Smart & Final, Liverpool (MEX), Roma Pharmacies (MEX),
Calimax, QuickAid Supply (#1 Amazon Medical Distributor)
- Healthcare: Kaiser Permanente, Right At Home In-home
Care, Visiting Angels Home Care, Advanced Integrated Medicine,
Caryn Health, Marquis Labs.
Forward-Looking Information
This press release contains "forward-looking information"
within the meaning of applicable securities laws. All statements
contained herein that are not clearly historical in nature may
constitute forward-looking information. In some cases,
forward-looking information can be identified by words or phrases
such as "may", "will", "expect", "likely", "should", "would",
"plan", "anticipate", "intend", "potential", "proposed",
"estimate", "believe" or the negative of these terms, or other
similar words, expressions and grammatical variations thereof, or
statements that certain events or conditions "may" or "will"
happen, or by discussions of strategy. The forward-looking
information contained herein includes, without limitation, the
distribution partnership and purchase order with USA Rapid Test, and the business and strategic
plans of the Company.
By their nature, forward-looking information is subject to
inherent risks and uncertainties that may be general or specific
and which give rise to the possibility that expectations,
forecasts, predictions, projections or conclusions will not prove
to be accurate, that assumptions may not be correct and that
objectives, strategic goals and priorities will not be achieved. A
variety of factors, including known and unknown risks, many of
which are beyond our control, could cause actual results to differ
materially from the forward-looking information in this press
release including, without limitation: the Company's ability to
comply with all applicable laws and governmental regulations
relating to its commercial products; the ability of the Company to
protect its intellectual property; impacts to the business and
operations of the Company due to the COVID-19 pandemic; having only
a limited operating history, the ability of the Company to access
capital to meet future financing needs; the Company's reliance on
management and key personnel; competition; changes in consumer
trends; foreign currency fluctuations; and general economic, market
or business conditions.
Additional risk factors can also be found in the Company's
continuous disclosure documents, which have been filed on SEDAR and
can be accessed at www.sedar.com. Readers are
cautioned to consider these and other factors, uncertainties and
potential events carefully and not to put undue reliance on
forward-looking information. The forward-looking information
contained herein is made as of the date of this press release and
is based on the beliefs, estimates, expectations and opinions of
management on the date such forward-looking information is made.
The Company undertakes no obligation to update or revise any
forward-looking information, whether as a result of new
information, estimates or opinions, future events or results or
otherwise or to explain any material difference between subsequent
actual events and such forward-looking information, except as
required by applicable law.
View original
content:https://www.prnewswire.com/news-releases/atmofizer-technologies-inc-signs-distribution-partnership-with-usa-rapid-test-301435863.html
SOURCE Atmofizer Technologies Inc.